Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, uncontrolled, multi-center phase II study to investigate efficacy and safety of ONO-4538 in patients with uterine cervical cancer, uterine corpus cancer, and soft-tissue sarcoma

Next Previous
Trial Profile

An open-label, uncontrolled, multi-center phase II study to investigate efficacy and safety of ONO-4538 in patients with uterine cervical cancer, uterine corpus cancer, and soft-tissue sarcoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Cervical cancer; Soft tissue sarcoma; Uterine cancer
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical

Most Recent Events

  • 01 Sep 2019 Results published in the Cancer Science
  • 05 Jun 2018 Primary endpoint (Overall response rate in patients with advanced or recurrent uterine cervical or corpus cancer) has been met.
  • 05 Jun 2018 Results (n=43) assessing efficacy and safety of nivolumab in patients with advanced or recurrent uterine cervical or corpus cancer, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top